For research use only. Not for therapeutic Use.
Vantictumab(CAT: I040652) is a human monoclonal antibody that targets the Frizzled (FZD) family of receptors, key components of the Wnt signaling pathway. By inhibiting Wnt/β-catenin signaling, Vantictumab disrupts cancer stem cell maintenance and tumor growth, making it a promising therapeutic agent in oncology research. It has been investigated for treating various solid tumors, including breast, pancreatic, and non-small cell lung cancers. Vantictumab’s mechanism also suggests potential synergy with conventional chemotherapy. It is primarily utilized in preclinical and clinical studies focused on targeted cancer therapy.
| CAS Number | 1345009-45-1 |
| Purity | ≥95% |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
